Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 6/20 | 0.49 |
| ▸ | RXRA | P19793 | 1/20 | 0.45 |
| ▸ | ITGB2 | P05107 | 4/20 | 0.42 |
| ▸ | ICAM1 | P05362 | 4/20 | 0.42 |
| ▸ | ITGAL | P20701 | 4/20 | 0.42 |
| ▸ | CKS1B | P61024 | 4/20 | 0.41 |
| ▸ | SKP1 | P63208 | 4/20 | 0.41 |
| ▸ | SKP2 | Q13309 | 4/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3265698 | 0.89 | CHRM4 (0.48) | CHRM4RXRAITGB2ICAM1ITGAL | |
| SCHEMBL3266796 | 0.87 | CHRM4 (0.48) | CHRM4 | |
| SCHEMBL239096 | 0.83 | CHRM4 (0.45) | CHRM4CKS1BSKP1SKP2 | |
| SCHEMBL1729606 | 0.83 | CHRM4 (0.57) | CHRM4RXRAITGB2ICAM1ITGAL | |
| SCHEMBL3267181 | 0.80 | CKS1B (0.44) | CHRM4CKS1BSKP1SKP2 | |
| SCHEMBL3268994 | 0.80 | SIRT2 (0.46) | CHRM4 | |
| SCHEMBL3268986 | 0.79 | HSD11B1 (0.41) | CHRM4CKS1BSKP1SKP2 | |
| SCHEMBL3265695 | 0.79 | SIRT2 (0.45) | CHRM4 | |
| SCHEMBL241775 | 0.79 | ACACB (0.44) | — | |
| SCHEMBL240877 | 0.78 | TGM2 (0.44) | CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | CHRM4 243/4885RXRA 1086/4885ITGB2 1624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.